Although these new hypoglycemic drugs have satisfying effects in the treatment of DKD, some side effects, just as the urinary tract infection of SGLT2 inhibitor, the gastrointestinal reaction of incretin hormone, the hyperkalemia of MRAs, limit their application in some patients. Here, SLC5A2 is linked to diabetic kidney disease.